格隆汇8月25日丨*ST长药(300391.SZ)公布半年度报告，公司报告期实现营业收入7,057.50万元，同比减 少4.18%，归属于上市公司股东的净利润-11,635.38万元，同比增加23.74%；公司报告期内营业收入同比 减少，主要原因是因资金紧张医药板块收入下降；归属于上市公司股东的净利润同比增加，主要原因是 本期计提应收账款、商誉减值准备减少。 ...

长江医药控股股份有限公司 长江医药控股股份有限公司董事会 编制单位：长江医药控股股份有限公司 金额单位：人民币万元 2025年8月26日 | | | 湖北新峰制药有 | 子公司 | 其他应 | 122.18 | 12.64 | 2.27 | 96.34 | 40.75 | 资金 | 非经营 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 限公司 | | 收款 | | | | | | 往来 | 性往来 | | | | 湖北长江丰医药 | 子公司 | 其他应 | 104.14 | 0 | 0 | 104.14 | 0 | 资金 | 非经营 | | | | 有限公司 | | 收款 | | | | | | 往来 | 性往来 | | | | 湖北明月和医药 | 子公司 | 其他应 | 6.95 | | 0.20 | | 7.15 | 资金 | 非经营 | | | | 科技有限公司 | | 收款 | | | | | | 往来 | 性往来 | | | | 恩施明群健康医 药产业科技有限 | 子公司 | 其他应 ...

2、本次计提信用减值准备、资产减值准备的资产范围和总金额 证券代码：300391 证券简称：*ST 长药 公告编号：2025-085 长江医药控股股份有限公司 关于2025年半年度计提资产减值准备的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 长江医药控股股份有限公司（以下简称"公司"或"本公司"）于 2025 年 8 月 22 日召开的第六届董事会第二次会议审议通过了《关于 2025 年半年度计提 资产减值准备的议案》。依据《深圳证券交易所创业板股票上市规则》等法律法 规相关规定，具体如下： 一、本次计提信用减值准备、资产减值准备情况 （一）本次计提信用减值准备、资产减值准备情况概述 1、本次计提信用减值准备、资产减值准备的原因 公司本次计提信用减值准备、资产减值准备，是依照《企业会计准则》及公 司会计政策的相关规定进行的。公司对截至 2025 年 6 月 30 日各类资产进行了全 面清查，并对各类资产进行了充分的评估和分析，本着谨慎性原则，公司需对可 能发生减值损失的相关资产进行计提减值准备。 公司对截至 2025 年 6 月 30 日存在可能发生减 ...

证券代码：300391 证券简称：*ST 长药 公告编号：2025-086 长江医药控股股份有限公司 关于 2025 年度日常关联交易预计的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 一、日常关联交易基本情况 （一）预计2025年度日常关联交易的基本情况 为充分拓展销售渠道，发挥相关方资源优势，促进公司产品销售，实现较好 经济效益，根据业务经营发展需要，长江医药控股股份有限公司（以下简称"公 司"）控股子公司湖北长江星医药股份有限公司（以下简称"长江星"）及/或其 子公司2025年度预计与公司关联法人湖北凤源春武当道茶生物科技有限公司（以 下简称"凤源春"）及其关联方因销售产品、商品发生日常关联交易，关联交易 总额预计不超过人民币2000万元（含税）。 公司于2025年8月22日召开了第六届董事会第二次会议，审议通过了《关于 2025年度日常关联交易预计的议案》，关联董事翁浩、赵守军回避表决。本议案 经公司第六届董事会独立董事第一次专门会议审议通过。本次关于2025年度日常 关联交易预计的事项未达到股东会审批标准。 （二）预计日常关联交易类别和金额 单 ...

证券代码：300391 证券简称：*ST长药 公告编号：2025-087 长江医药控股股份有限公司 重大诉讼的进展公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 重要内容提示： 原告嘉兴骏鹰仓实投资合伙企业(有限合伙)与被告长江医药控股股份有限 公司、第三人湖北长江大药房连锁有限公司债权人代位权纠纷案，十堰市中级人 民法院于2025年8月15日判决。本案涉案金额18,947.85万元，涉及的82.13万元 预计将对公司当期损益产生影响。 一、诉讼事项的基本情况 2025年8月21日，长江医药控股股份有限公司（以下简称"公司"）收到湖 北省十堰市中级人民法院送达的判决书。湖北省十堰市中级人民法院所在地为十 堰市张湾区浙江路66号。诉讼各方当事人如下： 原告：嘉兴骏鹰仓实投资合伙企业(有限合伙)，委派代表张程程；委托诉讼 代理人陈宇、曾若霖，湖北楚阳律师事务所律师。 被告：长江医药控股股份有限公司，法定代表人胡士会；委托诉讼代理人周 郎惠，湖北汉丰律师事务所律师。 第三人：湖北长江大药房连锁有限公司，法定代表人阳勇；委托诉讼代理人 周浩，广东盛兆冠獬律师事务所 ...

特此公告。 长江医药控股股份有限公司董事会 证券代码：300391 证券简称：*ST 长药 公告编号：2025-082 长江医药控股股份有限公司 2025 年半年度报告披露提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 2025年8月22日，长江医药控股股份有限公司（以下简称"公司"）召开第六 届董事会第二次会议，审议通过了公司2025年半年度报告及摘要。为使投资者全 面了解公司的经营成果、财务状况等，公司2025年半年度报告及摘要于2025年8月 26日在中国证监会指定信息披露网站巨潮资讯网上披露，敬请投资者注意查阅。 2025年8月26日 ...

证券代码：300391 证券简称：*ST 长药 公告编号：2025-079 长江医药控股股份有限公司 第六届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 一、董事会会议召开情况 长江医药控股股份有限公司（以下简称"公司"）第六届董事会第二次会议于 2025年8月22日现场加通讯表决方式在公司会议室召开，会议通知已于2025年8月12 日以电子邮件方式送达。本次会议由王波先生主持，应参与表决董事9人，实际参 与表决董事9人，其中翁浩先生、高应会先生、顾紫光先生、韩庆凯先生以通讯方 式出席并表决。本次会议为董事会定期会议，召集、召开的程序、方式符合有关法 律、行政法规、部门规章、规范性文件和公司章程规定。 二、董事会会议审议情况 1、关于2025年第一季度财务报告会计差错更正的议案； 本议案经公司董事会审计委员会、独立董事专门会议审议通过。 详情参见与本公告同日披露于巨潮资讯网的《关于2025年第一季度财务报告会 计差错更正的公告》、《2025年第一季度报告（更正后）》。 表决情况：赞成：9票；反对：0票；弃权：0票 表决结果：通过。 ...

长江医药控股股份有限公司 2025 年半年度报告全文 长江医药控股股份有限公司 2025 年半年度报告 2025-084 2025 年 8 月 26 日 1 长江医药控股股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证半年度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法 律责任。 公司负责人胡士会、主管会计工作负责人杨英环及会计机构负责人(会计 主管人员)杨英环声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 目前，公司已进入预重整阶段，但公司能否进入重整程序存在不确定 性。如果法院裁定受理公司重整申请，根据《深圳证券交易所创业板股票上 市规则》相关规定，公司股票交易将被实施退市风险警示。即使法院正式受 理重整申请，后续仍然存在因重整失败而被宣告破产并被实施破产清算的风 险。如果公司因重整失败而被宣告破产，则根据《深圳证券交易所创业板股 票上市规则》相关规定，公司股票将面临被终止上市的风险。 本报告中如有涉及未来的计划、经营目标、业绩预测等方面的内容，均不 ...

[Key Disclosure Information](index=1&type=section&id=Key%20Disclosure%20Information) The report confirms the board and management's assurance of the quarterly report's accuracy and completeness, noting it remains unaudited - The board of directors, supervisory board, and senior management guarantee the truthfulness, accuracy, and completeness of the quarterly report, free from false records, misleading statements, or major omissions, assuming individual and joint legal responsibility[3](index=3&type=chunk) - The company's principal, chief financial officer, and head of accounting department declare the financial information in the quarterly report is true, accurate, and complete[3](index=3&type=chunk) - This first quarter report is unaudited[4](index=4&type=chunk)[41](index=41&type=chunk) [I. Key Financial Data](index=2&type=section&id=I.%20Key%20Financial%20Data) The company's Q1 2025 financial performance significantly deteriorated, with revenue down **22.50%**, net loss attributable to shareholders widening by **28.01%**, and operating cash flow plummeting by **118.90%**; shareholder equity remained negative and further declined [ (I) Key Accounting Data and Financial Indicators](index=2&type=section&id=%28I%29%20Key%20Accounting%20Data%20and%20Financial%20Indicators) In Q1 2025, revenue and net profit significantly declined, operating cash flow worsened, EPS loss expanded, total assets slightly grew, but shareholder equity remained negative and further decreased Key Accounting Data and Financial Indicators | Indicator | Current Period | Prior Year Period | YoY Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue (RMB) | 45,795,675.76 | 59,091,762.31 | -22.50% | | Net Profit Attributable to Shareholders (RMB) | -60,812,317.13 | -47,505,902.27 | -28.01% | | Net Profit Attributable to Shareholders Excluding Non-recurring Items (RMB) | -62,639,023.43 | -45,659,634.61 | -37.19% | | Net Cash Flow from Operating Activities (RMB) | -71,835,780.49 | -32,816,721.93 | -118.90% | | Basic Earnings Per Share (RMB/share) | -0.1736 | -0.1356 | -28.02% | | Diluted Earnings Per Share (RMB/share) | -0.1736 | -0.1356 | -28.02% | | Weighted Average Return on Net Assets | -13.13% | -27.72% | 14.59% | | **Period-End Indicators** | **Current Period-End** | **Prior Year-End** | **Change from Prior Year-End (%)** | | Total Assets (RMB) | 2,042,496,723.36 | 1,995,717,642.12 | 2.34% | | Shareholders' Equity Attributable to Listed Company (RMB) | -493,652,976.34 | -432,840,659.21 | -14.05% | [ (II) Non-recurring Gains and Losses Items and Amounts](index=2&type=section&id=%28II%29%20Non-recurring%20Gains%20and%20Losses%20Items%20and%20Amounts) Total non-recurring gains and losses for the period amounted to **RMB 1,826,706.30**, primarily from fair value changes in financial assets and debt restructuring, partially offsetting non-current asset disposal losses and non-operating expenses Non-recurring Gains and Losses Items and Amounts | Item | Amount for Current Period (RMB) | Description | | :--- | :--- | :--- | | Gains/Losses on Disposal of Non-current Assets | -101,726.14 | | | Government Grants Included in Current Profit/Loss | 315,367.93 | | | Gains/Losses from Fair Value Changes of Financial Assets and Liabilities Held by Non-financial Enterprises and Disposal of Financial Assets and Liabilities | 2,200,000.00 | | | Debt Restructuring Gains/Losses | 700,000.00 | | | Other Non-operating Income and Expenses Apart from the Above | -224,147.09 | | | Impact on Minority Interests (After Tax) | 1,062,788.40 | | | **Total** | **1,826,706.30** | -- | - The company has not classified any non-recurring gains and losses items listed in 'Interpretive Announcement No. 1 on Information Disclosure by Companies Issuing Securities to the Public—Non-recurring Gains and Losses' as recurring items[7](index=7&type=chunk)[8](index=8&type=chunk) [ (III) Changes and Reasons for Key Accounting Data and Financial Indicators](index=3&type=section&id=%28III%29%20Changes%20and%20Reasons%20for%20Key%20Accounting%20Data%20and%20Financial%20Indicators) Multiple financial indicators saw significant year-over-year changes, including a **52.27%** rise in provisions, **22.50%** revenue decline, **181.54%** surge in financial expenses, **118.90%** deterioration in operating cash flow, and **117.58%** increase in financing cash flow Changes and Reasons for Key Accounting Data and Financial Indicators | Item | Current Period (RMB) | Prior Year Period (RMB) | YoY Change (%) | Reason for Change | | :--- | :--- | :--- | :--- | :--- | | Provisions | 45,808,696.12 | 30,084,303.04 | 52.27% | Due to increase in pending lawsuits | | Operating Revenue | 45,795,675.76 | 59,091,762.31 | -22.50% | Due to year-over-year decrease in pharmaceutical sector revenue | | Operating Cost | 47,500,988.09 | 54,604,638.79 | -13.01% | Due to year-over-year decrease in pharmaceutical sector revenue | | Financial Expenses | 34,973,280.67 | 12,422,196.09 | 181.54% | Due to interest accrued for lawsuits | | Credit Impairment Losses | -31,953,818.21 | -47,021,483.23 | 32.04% | Due to year-over-year decrease in allowance for doubtful accounts | | Non-operating Expenses | 289,356.56 | 3,692,085.55 | -92.16% | Due to compensation expenses arising from product quality issues in the prior year period | | Net Cash Flow from Operating Activities | -71,835,780.49 | -32,816,721.93 | -118.90% | Due to decrease in sales collections | | Net Cash Flow from Financing Activities | 68,545,138.96 | 31,502,907.79 | 117.58% | Due to increase in borrowings | [II. Shareholder Information](index=3&type=section&id=II.%20Shareholder%20Information) As of the reporting period end, the company had **20,224** common shareholders; the top ten shareholders' holdings show Changxing Shengshifenghua Business Co., Ltd. as the largest shareholder with **10.11%**, most of its shares pledged, and the company is unaware of any related party relationships or concerted actions among shareholders [ (I) Total Number of Common Shareholders and Top Ten Shareholders' Holdings](index=3&type=section&id=%28I%29%20Total%20Number%20of%20Common%20Shareholders%20and%20Top%20Ten%20Shareholders%27%20Holdings) At the end of the reporting period, there were **20,224** common shareholders and no preferred shareholders with restored voting rights; among the top ten, Changxing Shengshifenghua Business Co., Ltd. was the largest shareholder with **10.11%**, holding **21,002,800** pledged shares, while Shouguang Kangyue Investment Co., Ltd. had **9,500,000** frozen shares - The total number of common shareholders at the end of the reporting period was **20,224**, and the total number of preferred shareholders with restored voting rights was **0** at the end of the reporting period[12](index=12&type=chunk) Top Ten Common Shareholders' Holdings | Shareholder Name | Shareholder Nature | Holding Ratio (%) | Number of Shares (shares) | Pledged, Marked, or Frozen Status | | :--- | :--- | :--- | :--- | :--- | | Changxing Shengshifenghua Business Co., Ltd. | Domestic Non-state-owned Legal Person | 10.11% | 35,423,600.00 | Pledged 21,002,800.00 | | Shanghai Yucong Asset Management Co., Ltd. - Yucong Tianshun No. 2 Private Securities Investment Fund | Other | 5.99% | 21,000,000.00 | Not Applicable 0.00 | | Liu Lili | Domestic Natural Person | 5.05% | 17,681,253.00 | Not Applicable 0.00 | | Shouguang Kangyue Investment Co., Ltd. | Domestic Non-state-owned Legal Person | 3.46% | 12,114,547.00 | Frozen 9,500,000.00 | | Xu Guifang | Domestic Natural Person | 0.78% | 2,732,600.00 | Not Applicable 0.00 | | Wang Fugen | Domestic Natural Person | 0.70% | 2,461,250.00 | Not Applicable 0.00 | | Li Yufang | Domestic Natural Person | 0.54% | 1,900,005.00 | Not Applicable 0.00 | | Ma Junping | Domestic Natural Person | 0.53% | 1,852,450.00 | Not Applicable 0.00 | | Chen Naping | Domestic Natural Person | 0.52% | 1,836,450.00 | Not Applicable 0.00 | | Hao Kai | Domestic Natural Person | 0.52% | 1,808,050.00 | Not Applicable 0.00 | - The company is unaware of any associated relationships among shareholders or whether they constitute concerted parties as defined by the "Measures for the Administration of the Acquisition of Listed Companies"[13](index=13&type=chunk) - Shareholder Hao Kai holds **800,000** shares through a common securities account and **1,008,050** shares through a Zheshang Securities Co., Ltd. client credit trading guarantee securities account, totaling **1,808,050** shares[13](index=13&type=chunk) [ (II) Preferred Shareholder Information](index=4&type=section&id=%28II%29%20Preferred%20Shareholder%20Information) The company has no preferred shareholders - The company has no preferred shareholders[14](index=14&type=chunk) [ (III) Changes in Restricted Shares](index=4&type=section&id=%28III%29%20Changes%20in%20Restricted%20Shares) There were no changes in the company's restricted shares - There were no changes in the company's restricted shares[14](index=14&type=chunk) [III. Other Significant Matters](index=4&type=section&id=III.%20Other%20Significant%20Matters) The company faces severe going concern uncertainties, including negative net assets, huge accumulated losses, significant revenue decline, numerous overdue debts, and frozen bank accounts; additionally, the company has entered pre-reorganization, its subsidiaries have been ruled for bankruptcy reorganization, posing significant risks of reorganization failure and stock delisting [ (I) Risk Warning for Significant Uncertainties Related to Going Concern in the 2024 Annual Audit Report](index=4&type=section&id=%28I%292024%20Annual%20Audit%20Report%20Risk%20Warning%20for%20Significant%20Uncertainties%20Related%20to%20Going%20Concern) As of year-end 2024, the company had negative net assets, substantial accumulated losses, three consecutive years of negative operating cash flow, and severe revenue decline; numerous overdue debts led to frozen bank accounts and seized assets, with subsidiaries entering bankruptcy reorganization, indicating significant going concern uncertainties - As of December 31, 2024, the company's consolidated financial statements showed net assets attributable to the parent company of **-RMB 432,840,659.21**, undistributed profits of **-RMB 1,589,707,417.48**, and net profit attributable to parent company shareholders of **-RMB 627,961,728.50** for 2024[14](index=14&type=chunk) - The company's net operating cash flow has been negative for **3** consecutive years, with a huge accumulated loss[14](index=14&type=chunk) - The company's operating revenue has severely declined from **RMB 1.615 billion** in 2022 and **RMB 1.198 billion** in 2023 to **RMB 112 million** in 2024[14](index=14&type=chunk) - Numerous overdue debts have led to lawsuits from some creditors, resulting in a large number of frozen bank accounts and seized assets[14](index=14&type=chunk) - On January 20, 2025, the Shiyan Intermediate People's Court of Hubei Province decided to initiate pre-reorganization for Changyao Holdings; on March 10, 2025, the Shiyan Intermediate People's Court ruled for the bankruptcy reorganization of subsidiary Hubei Changjiang Star Pharmaceutical Co., Ltd.; on March 27, 2025, the Shiyan Intermediate People's Court ruled for the consolidated reorganization of seven subsidiaries[15](index=15&type=chunk) - The aforementioned matters or circumstances indicate significant uncertainties regarding Changyao Holdings' ability to continue as a going concern without major changes[16](index=16&type=chunk) [ (II) Risk of Reorganization Failure](index=4&type=section&id=%28II%29%20Risk%20of%20Reorganization%20Failure) The company has entered pre-reorganization, but its formal entry into reorganization remains uncertain; if the court accepts the reorganization application, the company's stock will be subject to delisting risk warnings, and if reorganization fails, the company may be declared bankrupt and liquidated, facing the risk of stock delisting - The company entered the pre-reorganization phase on January 20, 2025, but whether it can formally enter the reorganization process remains uncertain[18](index=18&type=chunk) - If the court rules to accept the company's reorganization application, the company's stock trading will be subject to delisting risk warnings[18](index=18&type=chunk) - Even if the court formally accepts the reorganization application, there is still a risk of being declared bankrupt and liquidated due to reorganization failure, which may lead to the company's stock facing the risk of delisting[18](index=18&type=chunk) [ (III) Risk of Stock Delisting](index=5&type=section&id=%28III%29%20Risk%20of%20Stock%20Delisting) The company's stock has been subject to delisting risk warnings since April 22, 2025; according to the "Shenzhen Stock Exchange ChiNext Stock Listing Rules," if the company's 2025 audited total profit, net profit, or net profit after non-recurring items is negative and operating revenue after deduction is below **RMB 100 million**, or if net assets at year-end are negative, or if the financial report receives a non-standard audit opinion, the company's stock will face delisting risk - The company's stock trading has been subject to delisting risk warnings since April 22, 2025[19](index=19&type=chunk) - If the company's 2025 audited total profit, net profit, or net profit after deducting non-recurring gains and losses is negative, and the operating revenue after deduction is below **RMB 100 million**, the Shenzhen Stock Exchange will decide to terminate the company's stock listing[19](index=19&type=chunk)[27](index=27&type=chunk) - If the company's 2025 audited net assets at year-end are negative, the Shenzhen Stock Exchange will decide to terminate the company's stock listing[20](index=20&type=chunk)[27](index=27&type=chunk) - If the company's 2025 financial accounting report receives a qualified, adverse, or disclaimer of opinion audit report, the Shenzhen Stock Exchange will decide to terminate the company's stock listing[21](index=21&type=chunk)[27](index=27&type=chunk) - Investors are kindly requested to pay attention to investment risks[28](index=28&type=chunk) [IV. Quarterly Financial Statements](index=5&type=section&id=IV.%20Quarterly%20Financial%20Statements) This section provides the company's consolidated balance sheet, consolidated income statement, and consolidated cash flow statement for Q1 2025, detailing the financial position, operating results, and cash flows at the end of the reporting period; the company did not adopt new accounting standards for the first time in this period, and the quarterly report is unaudited [ (I) Financial Statements](index=5&type=section&id=%28I%29%20Financial%20Statements) Includes the consolidated balance sheet, consolidated income statement, and consolidated cash flow statement, reflecting the company's assets, liabilities, owner's equity, revenue, expenses, profit, and cash inflows and outflows for Q1 2025 [1. Consolidated Balance Sheet](index=5&type=section&id=1.%20Consolidated%20Balance%20Sheet) As of March 31, 2025, the company's total assets were **RMB 2.042 billion**, a **2.34%** increase from the beginning of the period; total current assets were **RMB 1.185 billion**, and total non-current assets were **RMB 858 million**; total liabilities were **RMB 2.553 billion**, with current liabilities at **RMB 2.045 billion** and non-current liabilities at **RMB 508 million**; owner's equity attributable to the parent company was **-RMB 494 million**, minority interests were **-RMB 17 million**, and total owner's equity was **-RMB 511 million**, indicating persistently negative net assets Consolidated Balance Sheet | Item | Period-End Balance (RMB) | Period-Beginning Balance (RMB) | | :--- | :--- | :--- | | **Assets** | | | | Total Current Assets | 1,184,629,835.39 | 1,129,357,419.11 | | Total Non-current Assets | 857,866,887.97 | 866,360,223.01 | | **Total Assets** | **2,042,496,723.36** | **1,995,717,642.12** | | **Liabilities** | | | | Total Current Liabilities | 2,045,192,800.38 | 1,924,644,829.41 | | Total Non-current Liabilities | 508,055,500.27 | 492,427,835.02 | | **Total Liabilities** | **2,553,248,300.65** | **2,417,072,664.43** | | **Owner's Equity** | | | | Total Owner's Equity Attributable to Parent Company | -493,652,976.34 | -432,840,659.21 | | Minority Interests | -17,098,600.95 | 11,485,636.90 | | **Total Owner's Equity** | **-510,751,577.29** | **-421,355,022.31** | - Cash and cash equivalents at period-end amounted to **RMB 9,012,776.10**, while accounts receivable reached **RMB 1,023,063,349.86**[30](index=30&type=chunk)[31](index=31&type=chunk) - Other payables amounted to **RMB 1,324,188,274.25**, including interest payable of **RMB 12,738,377.66**[32](index=32&type=chunk) - Undistributed profits were **-RMB 1,650,519,734.61**, further deteriorating from the beginning of the period[32](index=32&type=chunk) [2. Consolidated Income Statement](index=7&type=section&id=2.%20Consolidated%20Income%20Statement) In Q1 2025, the company's total operating revenue was **RMB 45.80 million**, a **22.50%** year-over-year decrease; total operating costs were **RMB 106 million**, with financial expenses significantly increasing by **181.54%** year-over-year; the company reported a net loss of **RMB 89.40 million**, and net loss attributable to parent company owners was **RMB 60.81 million**, widening the loss compared to the prior year period Consolidated Income Statement | Item | Amount for Current Period (RMB) | Amount for Prior Period (RMB) | | :--- | :--- | :--- | | Total Operating Revenue | 45,795,675.76 | 59,091,762.31 | | Total Operating Costs | 106,127,907.23 | 89,749,307.79 | | Including: Operating Cost | 47,500,988.09 | 54,604,638.79 | | Selling Expenses | 2,939,791.68 | 5,103,682.48 | | Administrative Expenses | 19,053,546.04 | 16,085,180.97 | | Financial Expenses | 34,973,280.67 | 12,422,196.09 | | Credit Impairment Losses | -31,953,818.21 | -47,021,483.23 | | Operating Profit | -89,172,407.89 | -77,433,335.93 | | Total Profit | -89,396,554.98 | -81,120,269.42 | | Net Profit | -89,396,554.98 | -81,120,269.42 | | Net Profit Attributable to Parent Company Owners | -60,812,317.13 | -47,505,902.27 | | Basic Earnings Per Share | -0.1736 | -0.1356 | - Investment income for the current period was **RMB 2,900,000.00**, compared to **RMB 0** in the prior period[35](index=35&type=chunk) - Minority interest loss was **-RMB 28,584,237.85**, an improvement from **-RMB 33,614,367.15** in the prior period[36](index=36&type=chunk) [3. Consolidated Cash Flow Statement](index=9&type=section&id=3.%20Consolidated%20Cash%20Flow%20Statement) In Q1 2025, net cash flow from operating activities was **-RMB 71.84 million**, a **118.90%** year-over-year deterioration primarily due to reduced sales collections; net cash flow from investing activities turned positive to **RMB 1.17 million**, mainly from other cash received related to investing activities; net cash flow from financing activities was **RMB 68.55 million**, a **117.58%** year-over-year increase primarily due to increased borrowings; cash and cash equivalents balance at period-end was **RMB 3.29 million** Consolidated Cash Flow Statement | Item | Amount for Current Period (RMB) | Amount for Prior Period (RMB) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | -71,835,780.49 | -32,816,721.93 | | Net Cash Flow from Investing Activities | 1,174,560.80 | -2,690,657.00 | | Net Cash Flow from Financing Activities | 68,545,138.96 | 31,502,907.79 | | Net Increase in Cash and Cash Equivalents | -2,116,098.55 | -3,984,366.60 | | Cash and Cash Equivalents at Period-End | 3,289,786.32 | 2,316,745.24 | - Cash received from sales of goods and rendering of services for the current period was **RMB 39,130,032.28**, a year-over-year decrease of approximately **20.8%** from **RMB 49,400,392.01** in the prior period[38](index=38&type=chunk) - Cash paid for goods and services for the current period was **RMB 88,612,091.37**, a year-over-year increase of approximately **50.8%** from **RMB 58,777,551.13** in the prior period[39](index=39&type=chunk) - Other cash received related to investing activities was **RMB 1,320,000.00** for the current period, compared to **RMB 0** in the prior period[39](index=39&type=chunk) - Cash paid for debt repayment for the current period was **RMB 288,981.79**, a significant decrease from **RMB 16,548,619.51** in the prior period[40](index=40&type=chunk) [ (II) Adjustments for First-time Adoption of New Accounting Standards in 2025](index=11&type=section&id=%28II%29%20Adjustments%20for%20First-time%20Adoption%20of%20New%20Accounting%20Standards%20in%202025) The company did not adopt new accounting standards for the first time in 2025, thus no adjustments to the opening financial statements for the first year of adoption are required - The company did not adopt new accounting standards for the first time in 2025[41](index=41&type=chunk) [ (III) Audit Report](index=11&type=section&id=%28III%29%20Audit%20Report) The company's Q1 2025 report is unaudited - The company's first quarter report is unaudited[41](index=41&type=chunk)

2、本次会计差错更正事项仅对公司2025年第一季度报告中合并利润表的相关 项目及指标有影响。 公司于2025年8月22日召开第六届董事会第二次会议，审议通过了《关于2025 年第一季度财务报告会计差错更正的议案》，同意公司按照《企业会计准则第28 号——会计政策、会计估计变更和差错更正》《公开发行证券的公司信息披露编报 规则第19号——财务信息的更正及相关披露》的相关规定和要求，对相关会计差错 进行更正。公司本次会计差错更正仅涉及2025年第一季度合并利润表，具体情况如 下： 一、会计差错更正情况 证券代码：300391 证券简称：*ST 长药 公告编号：2025-080 长江医药控股股份有限公司 关于2025年第一季度财务报告会计差错更正的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 特别提示： 1、本次会计差错更正影响长江医药控股股份有限公司（以下简称"公司"） 2025年度第一季度合并利润表营业收入、营业总收入、营业成本、营业总成本，不 影响2025年第一季度合并资产负债表、合并现金流量表。 《企业会计准则第14号——收入》第三十四条："企业应当 ...